New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT07198165
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation, chemotherapy, and a targeted therapy) can improve outcomes for people with locally advanced rectal cancer. About 104 participants will receive the standard combination, with half also getting the immunotherapy. The goal is to see if the extra drug helps more tumors completely disappear before surgery and reduces the chance of cancer spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.